IDH1 and central nervous system cancer: Mutations in isocitrate dehydrogenase (IDH), particularly in IDH1 and IDH2, have emerged as critical molecular events in various cancers, most notably gliomas, acute myeloid leukemia (AML), and chondrosarcomas [19].